pI: 7.4419 |
Length (AA): 541 |
MW (Da): 61536 |
Paralog Number:
1
Signal peptide: N | GPI Anchor: N | Predicted trans-membrane segments: 0
Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable
Modbase 3D models:
There are 5 models calculated for this protein. More info on
these models, including the
models themselves is available at:
Modbase
Target Beg | Target End | Template | Template Beg | Template End | Identity | Evalue | Model Score | MPQS | zDope |
---|---|---|---|---|---|---|---|---|---|
31 | 328 | 1jwy (B) | 2 | 305 | 16.00 | 0.00000000058 | 0.83 | 0.65 | -0.58 |
33 | 328 | 2aka (B) | 6 | 303 | 16.00 | 0 | 0.66 | 0.72 | -0.77 |
2 | 425 | 4cid (A) | 3 | 442 | 33.00 | 0 | 1 | 1.12213 | -0.18 |
14 | 535 | 4cid (A) | 5 | 539 | 23.00 | 0 | 1 | 1.17898 | 0.36 |
417 | 540 | 4r61 (A) | 15 | 152 | 8.00 | 0 | 0.11 | 0.310605 | -0.24 |
Help me make sense of these data.
A more detailed description of these scores is available at the Modbase Model Evaluation Help Pages, and in the papers referenced therein.
PDB Structures:
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Upper 60-80% percentile | amastigotes, metacyclic. | Fernandes MC |
Fernandes MC | Dual Transcriptome Profiling of Leishmania-Infected Human Macrophages Reveals Distinct Reprogramming Signatures. |
Ortholog group members (OG5_127350)
Species | Accession | Gene Product |
---|---|---|
Arabidopsis thaliana | AT3G20290 | EPS15 homology domain 1 protein |
Arabidopsis thaliana | AT4G05520 | EPS15 homology domain 2 protein |
Brugia malayi | Bm1_25225 | EH-domain containing protein 3 |
Caenorhabditis elegans | CELE_W06H8.1 | Protein RME-1, isoform F |
Dictyostelium discoideum | DDB_G0282233 | hypothetical protein |
Drosophila melanogaster | Dmel_CG6148 | Putative Achaete Scute Target 1 |
Echinococcus granulosus | EgrG_000851900 | Receptor Mediated Endocytosis family member |
Entamoeba histolytica | EHI_052870 | ENTH domain protein, putative |
Entamoeba histolytica | EHI_152680 | EH-domain containing protein, putative |
Entamoeba histolytica | EHI_105270 | Receptor mediated endocytosis protein, putative |
Echinococcus multilocularis | EmuJ_000851900 | Receptor Mediated Endocytosis family member |
Homo sapiens | ENSG00000110047 | EH-domain containing 1 |
Homo sapiens | ENSG00000024422 | EH-domain containing 2 |
Homo sapiens | 30845 | EH-domain containing 3 |
Homo sapiens | 30844 | EH-domain containing 4 |
Leishmania braziliensis | LbrM.19.0590 | sarcoplasmic reticulum glycoprotein, putative,sarcalumenin precursor, putative |
Leishmania braziliensis | LbrM.20.1770 | hypothetical protein, conserved |
Leishmania donovani | LdBPK_190270.1 | Sarcalumenin, putative |
Leishmania donovani | LdBPK_342040.1 | Dynamin family, putative |
Leishmania infantum | LinJ.34.2040 | hypothetical protein, conserved |
Leishmania infantum | LinJ.19.0270 | sarcoplasmic reticulum glycoprotein, putative,sarcalumenin precursor, putative |
Leishmania major | LmjF.19.0280 | sarcoplasmic reticulum glycoprotein, putative,sarcalumenin precursor, putative |
Leishmania major | LmjF.34.2270 | hypothetical protein, conserved |
Leishmania mexicana | LmxM.19.0280 | sarcoplasmic reticulum glycoprotein, putative,sarcalumenin precursor, putative |
Leishmania mexicana | LmxM.33.2270 | hypothetical protein, conserved |
Loa Loa (eye worm) | LOAG_11153 | EH-domain-containing protein 3 |
Loa Loa (eye worm) | LOAG_01942 | hypothetical protein |
Loa Loa (eye worm) | LOAG_12119 | hypothetical protein |
Loa Loa (eye worm) | LOAG_13090 | hypothetical protein |
Mus musculus | 259300 | EH-domain containing 2 |
Mus musculus | ENSMUSG00000027293 | EH-domain containing 4 |
Mus musculus | ENSMUSG00000024065 | EH-domain containing 3 |
Mus musculus | ENSMUSG00000024772 | EH-domain containing 1 |
Neospora caninum | NCLIV_031580 | GA19392, related |
Oryza sativa | 4341894 | Os06g0687800 |
Oryza sativa | 4328363 | Os02g0158100 |
Oryza sativa | 4337342 | Os04g0669300 |
Onchocerca volvulus | OVOC8114 |
|
Onchocerca volvulus | OVOC9312 |
|
Plasmodium berghei | PBANKA_0402800 | EH domain-containing protein, putative |
Plasmodium falciparum | PF3D7_0304200 | EH domain-containing protein |
Plasmodium knowlesi | PKNH_0838900 | EH domain-containing protein, putative |
Plasmodium vivax | PVX_119335 | EH (for Eps15 Homology) domain containing protein |
Plasmodium yoelii | PY03528 | Plasmodium vivax PV1H14130_P |
Schistosoma japonicum | Sjp_0301270 | EH domain-containing protein 1, putative |
Schistosoma japonicum | Sjp_0002850 | EH domain-containing protein 1, putative |
Schistosoma mansoni | Smp_065180 | eh domain containing/past-1-related |
Schistosoma mansoni | Smp_019100 | eh domain containing/past-1-related |
Schmidtea mediterranea | mk4.002630.01 | |
Schmidtea mediterranea | mk4.009408.00 | |
Schmidtea mediterranea | mk4.000000.55 | |
Schmidtea mediterranea | mk4.003056.05 | |
Trypanosoma brucei gambiense | Tbg972.4.2340 | sarcoplasmic reticulum glycoprotein, putative |
Trypanosoma brucei gambiense | Tbg972.10.18120 | sarcoplasmic reticulum glycoprotein, putative,sarcalumenin precursor, putative |
Trypanosoma brucei | Tb927.10.14910 | Sarcalumenin, putative |
Trypanosoma brucei | Tb927.4.2380 | sarcoplasmic reticulum glycoprotein, putative |
Trypanosoma congolense | TcIL3000_10_12790 | Sarcalumenin, putative |
Trypanosoma cruzi | TcCLB.506559.270 | sarcoplasmic reticulum glycoprotein, putative |
Trypanosoma cruzi | TcCLB.506211.100 | Sarcalumenin, putative |
Trypanosoma cruzi | TcCLB.508895.30 | Sarcalumenin, putative |
Toxoplasma gondii | TGME49_231210 | sarcalumenin/eps15 family protein |
Gene/Ortholog | Organism | Phenotype | Source Study |
---|---|---|---|
Tb927.10.14910 | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (3 days) | alsford |
Tb927.10.14910 | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (6 days) | alsford |
Tb927.10.14910 | Trypanosoma brucei | significant loss of fitness in procyclic forms | alsford |
Tb927.10.14910 | Trypanosoma brucei | no significant loss or gain of fitness in differentiation of procyclic to bloodstream forms | alsford |
Tb927.4.2380 | Trypanosoma brucei | significant loss of fitness in bloodstream forms (3 days) | alsford |
Tb927.4.2380 | Trypanosoma brucei | significant loss of fitness in bloodstream forms (6 days) | alsford |
Tb927.4.2380 | Trypanosoma brucei | no significant loss or gain of fitness in procyclic forms | alsford |
Tb927.4.2380 | Trypanosoma brucei | significant loss of fitness in differentiation of procyclic to bloodstream forms | alsford |
CELE_W06H8.1 | Caenorhabditis elegans | embryonic lethal | wormbase |
PBANKA_0402800 | Plasmodium berghei | Dispensable | plasmo |
TGME49_231210 | Toxoplasma gondii | Essentiality uncertain | sidik |
yeastgenome | Systematic deletion of yeast genes | Saccharomyces Genome Database |
shigen | Profiling of E. coli Chromosome (PEC) | National Institute of Genetics, Japan |
nmpdr | Genome-scale essentiality datasets from published studies (M. tuberculosis) | National Microbial Pathogen Data Resource |
gerdes | Experimental determination and system-level analysis of essential genes in E. coli MG1655 | Gerdes et al., J Bacteriol. 2003 185:5673-84 |
alsford | High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome | Genome Res 2011, 21:915-924 |
keio | Systematic single-gene knock-out mutants of E. coli K12 | The Keio Collection |
neb | C. elegans RNAi phenotypes | Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs |
wormbase | C. elegans RNAi experiments | WormBase web site, http://www.wormbase.org, release WS170 |
blattner | Systematic mutagenesis of the E. coli (MG1655) genome | J Bacteriol 2004, 186:4921-4930 |
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please contact us.
Druggability index (range: 0 to 1): 0.3